The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...
Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...
AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...
GlobalData on MSN1d
Editas and Genevant team up to develop gene editing therapiesEditas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...
Zacks.com on MSN1d
EDIT Inks Collaboration Deal to Develop Novel Gene Editing TherapiesEditas Medicine, Inc. EDIT announced that it has entered into a collaboration and nonexclusive license agreement with ...
GlobalData on MSN18d
Editas trades part of Vertex CRISPR therapy licencing rights deal for $57mAmidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue stream ...
The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a ...
Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...
The global CRISPR and Cas Gene Market was valued at USD 1.8 billion in 2021. With an impressive projected growth rate of 30.2 ...
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback